docetaxel anhydrous has been researched along with nicardipine in 3 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (nicardipine) | Trials (nicardipine) | Recent Studies (post-2010) (nicardipine) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 2,646 | 444 | 312 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | nicardipine (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 8.314 | |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 8 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 4.2992 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.42 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 1.69 | |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 2.5 | |
| Cytochrome P450 2J2 | Homo sapiens (human) | 1.69 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 4.925 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 4.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bai, L; Bowen, NJ; Chen, Y; Cook, N; Danaher, A; Du, Y; Fu, H; Kucuk, O; Li, D; Li, X; Osunkoya, AO; Qui, M; Wu, D; Wu, JM; Wu, Y; Xie, ZR; Zhao, R | 1 |
1 review(s) available for docetaxel anhydrous and nicardipine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for docetaxel anhydrous and nicardipine
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models.
Topics: Animals; Apoptosis; Cell Line, Tumor; Docetaxel; Humans; Male; Mice; Nicardipine; Polycomb Repressive Complex 2; Prostatic Neoplasms | 2023 |